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Abstract
Growing consistent evidence indicates that hypofunction of N-methyl-D-aspartate (NMDA) transmission plays a pivotal role in 
the neuropathophysiology of schizophrenia. Hence, drugs which modulate NMDA neurotransmission are promising approaches 
to the treatment of schizophrenia. The aim of this article is to review clinical trials with novel compounds acting on the NMDA 
receptor (NMDA-R). This review also includes a discussion and translation of neuroscience into schizophrenia therapeutics. 
Although the precise mechanism of action of minocycline in the brain remains unclear, there is evidence that it blocks the neu-
rotoxicity of NMDA antagonists and may exert a differential effect on NMDA signaling pathways. We, therefore, hypothesize 
that the effects of minocycline on the brain may be partially modulated by the NMDA-R or related mechanisms. Thus, we have 
included a review of minocycline neuroscience. The search was performed in the PubMed, Web of Science, SciELO, and Lilacs 
databases. The results of glycine and D-cycloserine trials were conflicting regarding effectiveness on the negative and cognitive 
symptoms of schizophrenia. D-serine and D-alanine showed a potential effect on negative symptoms and on cognitive deficits. 
Sarcosine data indicated a considerable improvement as adjunctive therapy. Finally, minocycline add-on treatment appears to 
be effective on a broad range of psychopathology in patients with schizophrenia. The differential modulation of NMDA-R neu-
rosystems, in particular synaptic versus extrasynaptic NMDA-R activation and specific subtypes of NMDA-R, may be the key 
mediators of neurogenesis and neuroprotection. Thus, psychotropics modulating NMDA-R neurotransmission may represent 
future monotherapy or add-on treatment strategies in the treatment of schizophrenia.
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Schizophrenia is a disabling illness that affects ap-
proximately 1% of the world population (1) and is char-
acterized by positive, negative and cognitive symptoms. 
This psychiatric disorder encompasses symptoms such 
as delusions, hallucinations, disorganized thinking, apathy, 
and deterioration of social role functioning (1). In addition, 
patients with schizophrenia experience severe suffering 
and close to 10% of them commit suicide (1). The typical 
onset of this disease is in young adults, and its course is 
often chronic (1). 
Disruption of the dopaminergic system is implicated in the 
pathophysiology of schizophrenia. Conventional dopamine 
receptor-blocking antipsychotics are effective for positive 
symptoms, but they have limited effects on negative and 
cognitive symptoms (2). These symptoms possibly involve 
other neurotransmitter systems besides dopamine.
Emerging data indicate that hypofunction of glutamater-
gic N-methyl-D-aspartate receptor (NMDA-R) transmission 
plays a central role in the pathophysiology of schizophrenia 
(3,4).
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Hypothesis of NMDA-R hypofunction in schizophrenia
Emerging data indicate a direct involvement of the 
glutamatergic system in the pathophysiology of schizo-
phrenia core symptoms. Complementary to the dopamine 
hypothesis, the hypofunction of the ionotropic glutamate 
NMDA-R has been proposed as a model of schizophrenia 
in humans (4). Thus far, there have been many clinical trials 
with novel compounds acting on the NMDA-R.
The glutamatergic hypothesis of schizophrenia postu-
lates that the dysfunction of neurotransmission mediated 
by the NMDA-R might represent a primary deficit in this 
disorder (4). The ability of phencyclidine, ketamine, and 
other NMDA-R antagonists to induce schizophrenia-like 
symptoms in healthy volunteers and to exacerbate psy-
chosis in schizophrenic patients is the most compelling 
evidence of a relationship between NMDA-R function and 
schizophrenia (4,5).
The NMDA-R antagonist-induced psychosis models are 
closer to certain clinical aspects of schizophrenia than the 
amphetamine/dopamine model, mainly by the generation 
of negative symptoms and cognitive deficits (4,5). Thus, the 
potentiation of NMDA-R transmission might be a promising 
treatment approach to schizophrenia. 
Drugs that modulate NMDA-R neurotransmission
Since glutamate and direct-acting NMDA-R agonists 
may be neurotoxic and are known to cause excitotoxicity, the 
strategy used in the last decade has relied on agonists at the 
strychnine-insensitive glycine receptor site of the NMDA-R 
complex (6). Therefore, experiments have been carried out 
on full agonists like glycine, D-serine and D-alanine, on the 
partial agonist D-cycloserine, and on sarcosine. 
NMDA-R full agonists
Glycine is a small naturally occurring amino acid that 
functions as an endogenous co-agonist at the strychnine-
insensitive glycine binding site, being a prerequisite for 
the activation of the NMDA ion channel (7). Glycine is not 
synthesized by glutamatergic neurons and a small amount 
is released from glycine neurons, so that the neighboring 
glial cells are the main source of the glycine available for 
the NMDA-R (8). The permeation of glycine into the brain 
barrier after peripheral administration is the lowest for any 
naturally occurring amino acid and high oral doses of glycine 
must be administered to achieve significant elevations in 
its central nervous system (CNS) levels (7).
D-serine is an endogenous co-transmitter enriched in 
corticolimbic regions and distributed in parallel with the 
NMDA-R (9,10), acting as an endogenous full agonist at 
the NMDA-R-associated glycine site (9,10). D-serine can be 
derived from L-serine by serine racemase (SR) enzymatic 
conversion (8,9). Although initial studies have suggested 
that this enzyme was localized in glial cells, a recent inves-
tigation using novel SR knockout mice as negative controls 
pointed out that SR was co-localized with neuron-specific 
nuclear proteins, with SR expression being observed in 
GABAergic and glutamatergic neurons, but not in glia (9). 
In addition, serum and cerebrospinal fluid levels of D- and 
L-serine and D-serine ratio (D-serine/total serine) may be 
altered in schizophrenia, as demonstrated by reports of 
reduction of the D-serine ratio in the cerebrospinal fluid of 
drug-naive schizophrenic patients (3) and by decreased 
serum levels of D-serine in patients with schizophrenia (5). 
These data suggest that D-serine synthesis or metaboliza-
tion may be altered in schizophrenia, highlighting a pos-
sible reduction of SR activity (3,5). Moreover, D-serine has 
high affinity for the glycine site on NMDA-R and has the 
advantage of being more permeable than glycine through 
the blood-brain barrier, thus requiring a reduced amount 
per dose (8,10).
D-alanine, as well as D-serine, is an endogenous D-
amino acid present in the human CNS (11) and is a selective 
and potent agonist at the NMDA-R glycine site (11).
NMDA-R partial agonist
D-cycloserine, an analog of D-serine, is an antituber-
culous drug rarely used nowadays due to its adverse psy-
chiatric effects including anxiety, psychosis and seizures at 
doses of 500-2000 mg (12). D-cycloserine freely crosses 
the blood-brain barrier and has good bioavailability to the 
brain (13). It is a partial agonist at the glycine recognition 
site at lower doses, with agonist properties over a narrow 
dose range; hence, it can exhibit antagonist activity at 
higher concentrations. Additionally, D-cycloserine has ap-
proximately 40-60% activity compared to glycine and the 
glycine modulatory site of the NMDA-R (13).
Glycine transporter-1 inhibitor
Sarcosine (or N-methylglycine), a nonessential amino 
acid, is an endogenous antagonist of glycine transporter-1 
(glycine-T1). Glycine-T1 is located in the glial cells and its 
reuptake pump is the main route of inactivation of synaptic 
glycine. Therefore, the inhibition of glycine-T1 reuptake 
can increase glycine levels in the glutamatergic synapses 
and consequently augment NMDA-R transmission (8). 
Sarcosine is a natural occurring glycine-T1, which potenti-
ates the action of glycine on the NMDA glycine site and can 
enhance NMDA neurotransmission (14).
Glycinergic agents and targets of NMDA-R modulation 
are summarized in Figure 1.
NMDA-R augmentation
Recent studies have supported the idea that increas-
ing NMDA-R function may be an effective approach to the 
treatment of schizophrenia (15). Two recent reviews have 
been published about the use of glycinergic agents for this 
purpose (15,16). Tuominem et al. (15) published a sys-
tematic review and meta-analysis that comprised eighteen 
short-term trials using glycine, D-serine or D-cycloserine to 
increase the antipsychotic action. These investigators also 
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included ampakine CX516, an experimental drug that acts as 
an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid 
(AMPA) receptor agonist. Glycine and D-serine were suc-
cessful in reducing the negative symptoms of schizophrenia 
and the magnitude of the effect was moderate. D-cycloserine 
had a less efficient action on negative symptoms. On the 
other hand, positive symptoms failed to respond to glycin-
ergic medication and there were no significant effects of 
glycine or D-serine on cognitive functioning.
Shim et al. (16), in a review of the results of glyciner-
gic agents in the treatment of schizophrenia, proposed a 
polypharmacy of glycine site potentiators in addition to 
antipsychotic medication to stop neurodegeneration in 
schizophrenia. In addition, they suggested that drugs acting 
on other sites of the NMDA-R could also be effective in the 
treatment of the disorder.
Hypothesis of NMDA-R modulation by minocycline
Minocycline is a second-generation tetracycline with a 
broad spectrum of antimicrobial activities and anti-inflam-
matory properties. There is growing evidence showing 
neuroprotective effects of minocycline in several animal and 
human models of neurological diseases, including Parkin-
son’s disease, amyotrophic lateral sclerosis, Huntington’s 
disease, and ischemia (17).
Translational neuroscientific data from animal and hu-
man studies indicate that minocycline may be a potential 
treatment for schizophrenia. In the published literature, the 
first evidence indicating the antipsychotic efficacy of mino-
cycline was observed in a patient with Huntington’s disease, 
a case report from Canada (18). This clinical observation 
indicated the potential antipsychotic efficacy of this drug in 
schizophrenia. Zhang et al. (19) observed that pretreatment 
of mice with minocycline (40 mg/kg) significantly attenuated 
the level of dopamine in the striatum after repeated admin-
istration of methamphetamine. The same group (20) found 
that pretreatment with minocycline (40 mg/kg) reduced the 
increase of extracellular dopamine levels in the frontal cortex 
and striatum of mice after administration of the NMDA-R 
antagonist dizolcipine. Moreover, subsequent subchronic 
administration of minocycline considerably reduced the 
cognitive deficits induced by the NMDA-R antagonist phen-
cyclidine in mice (21) and reversed the cognitive effects of 
the NMDA-R antagonist MK801 in rats (22).
The neuroprotective action of minocycline can occur 
indirectly by inhibition of microglial activation and prolif-
Figure 1. Allosteric modulation of NMDA-R transmission by glycinergic agents. NMDA = N-methyl-D-aspartate; GLY-T1 = type-1 glycine trans-
porter; GLY-T2 = type-2 glycine transporter; SHMT = serine hydroxymethyl transferase; SNAT = specific neutral amino acid transporter. *The 
pathway for D-serine release from neurons is unknown. Glycinergic agents (glycine, D-serine, D-alanine or D-cycloserine) are obligatory co-
agonists at the strychnine-insensitive glycine binding site of NMDA receptors. Small amounts of glycine are released from glycinergic neurons 
and are taken back up by a GLY-T2 located in these neurons. However, most of the glycine available in the synaptic cleft is released by glial 
cells through a reversed GLY-T1. Glycine can be taken up into glial cells by GLY-T1 or through a glial specific neutral amino acid transporter. 
Glycine can also be converted from L-serine in glial cells through SHMT action. It is noteworthy that glycine reuptake by GLY-T1 in glial cells 
limits the availability of glycine in the synaptic cleft. L-serine can also be converted to D-serine by serine racemase in GABAergic or glutamater-
gic neurons. D-serine availability in the synaptic cleft is limited through its reuptake by amino acid transporter Asc-1 located in these neurons.
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eration and nitric oxide synthase inhibition (17). There are 
also influences on caspase expression and cytochrome c 
release, with an anti-apoptotic property, among others (17). 
Although the precise mechanism of action of minocycline 
remains unclear, the latest studies conducted with this 
agent suggest effects related to the glutamatergic system, 
in addition to its action as an anti-apoptotic drug. In fact, 
minocycline reversed several NMDA-R antagonist effects 
in animal studies and showed good results in the treatment 
of patients with schizophrenia (23,24). Thus, the hypothesis 
was raised that minocycline indirectly modulates NMDA-R 
transmission.
Furthermore, minocycline may exert a differential action 
on NMDA-R signaling pathways (described in the Discussion 
section). Consequently, the data about the three studies of 
minocycline in patients with schizophrenia were included 
in the present review.
The objective of this review is to identify and analyze 
clinical trials with NMDA-R transmission modulation and mi-
nocycline for the treatment of patients with schizophrenia.
Methods
The search was carried out in the PubMed, Web of Sci-
ence, SciELO, and Lilacs databases using the key words 
schizophrenia, NMDA agonist, glycine, serine, glutamate, 
clinical trial, and minocycline, up to September 2008. It 
contemplated only clinical trials with NMDA-R transmis-
sion modulation in the treatment of schizophrenia, with no 
year or language limits. We also inspected the reference 
lists of the reviewed articles to identify additional trials. We 
excluded animal or in vitro studies, review or meta-analysis 
articles, and studies on healthy volunteers. The present 
review covered 36 clinical trials.
Results
There were 27 randomized placebo-controlled double-
blind studies (2,6,7,10-12,14,23,25-42), 8 non-randomized 
trials (43-51), and 1 case report. Except for two trials 
(42,49) with drug-free patients, all other studies involved 
adjuvant therapy for antipsychotic treatment. Clinical as-
sessments were performed biweekly throughout most of 
the investigations.
The most used inclusion criteria were schizophrenia 
diagnosis according to the Diagnostic and Statistical Manual 
(DSM), primary deficit syndrome (using the Schedule for the 
Deficit Syndrome), minimum score of 30 on the Scale for 
the Assessment of Negative Symptoms (SANS), and use 
of a stable antipsychotic dose for more than three months. 
Exclusion criteria comprised comorbidity with substance 
abuse, major depression, serious clinical diseases, neuro-
logical diseases, and additional use of other psychotropic 
medications.
A combination of various scales was used for the evalu-
ation of clinical efficacy: Positive and Negative Symptoms 
Scale (PANSS), Brief Psychiatric Research Scale (BPRS), 
SANS, Global Assessment Scale (GAS), and Clinical Global 
Impression (CGI). The PANSS and/or SANS were used in 
almost all of the studies. Eleven trials (10,12,23,28,31,34,
37,38,47,48,50) assessed specific cognitive tests.
To facilitate the presentation of the results, studies were 
divided into four groups: 1) glycine, 2) D-cycloserine, 3) D-
alanine, D-serine and sarcosine, and 4) minocycline.
Glycine
Twelve articles were selected regarding the addition of 
glycine to the antipsychotic treatment as usual (Table 1), 
including 9 placebo-controlled double-blind trials (divided 
into 4 parallel and 5 crossover studies) (2,7,25-31), and 3 
open-label trials (43-45). The duration of the studies ranged 
from 6 to 28 weeks. The first studies (25,43,44) used low 
doses, including 10, 15 and 30 g/day. However, the glycine 
dose needs to be higher to sufficiently cross the blood-brain 
barrier, and most of the trials subsequently administered 
higher doses (60 or 0.8 g·kg-1·day-1).
For heuristic purposes, the results shown in Table 1 are 
analyzed in three distinct groups according to the type of 
antipsychotic used.
Glycine added to conventional antipsychotics
Eight trials evaluated the addition of glycine to typical 
antipsychotics (25-27,29,31,43-45) and none of them ob-
served any beneficial effect of glycine on positive symptoms. 
Rosse et al. (43) published a pilot study with 6 patients in 
which no significant results were obtained regarding the 
negative symptoms of schizophrenia. However, this study 
(43) was done with a low dose of glycine (10.8 g/day), 
which could explain the lack of effectiveness. The seven 
other investigations showed a beneficial effect on negative 
symptoms.
In 2007, Buchanan et al. (31) published the Cognitive 
and Negative Symptoms in Schizophrenia Trial (CONSIST), 
a randomized double-blind study with a duration of 16 
weeks and with the participation of 4 sites in the United 
States and one site in Israel. A total of 157 patients were 
recruited and randomized to glycine, D-cycloserine and 
placebo groups. The study suggested that glycine is not an 
effective therapeutic option for treating negative symptoms. 
Nevertheless, post hoc analyses revealed that, among sub-
jects receiving conventional antipsychotics, the 8 subjects 
randomly assigned to glycine had a greater decrease in 
the SANS total score compared to the 7 subjects randomly 
assigned to placebo. This trial also showed no significant 
difference in treatment response between patients with 
and without deficit syndrome. Nonetheless, tendencies to 
greater negative symptom reductions for both the glycine 
and D-cycloserine groups compared with placebo were 
observed in inpatients, but not in outpatients. 
Moreover, the CONSIST (31) was the only study that 
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assessed specific cognitive tests, detecting no significant re-
sults compared to placebo. Three other trials (26,27,29) evalu-
ated the cognitive effects of glycine based on clinical ratings 
(PANSS cognitive subscale) rather than neuropsychological 
examination, showing a positive result in cognitive functioning. 
Nevertheless, it is noteworthy that these three investigations 
(26,27,29) included a relatively small patient sample size and 
short-term glycine treatment.
Glycine added to second-generation antipsychotics
Four trials appraised the addition of glycine to second-
generation antipsychotics (7,29,31,45). A 6-week double-
blind crossover trial (7) registered a significant reduction of 
positive symptoms while the other three (29,31,45) did not 
exhibit a significant change of positive symptoms.
Three studies (7,29,45) provided evidence for a reduction 
of negative symptoms. However, these clinical trials were 
conducted on small samples over short periods of time, while 
the CONSIST (31) found no significant effect compared to 
placebo.
Once more, the CONSIST (31) was the only study that 
applied specific cognitive tests, obtaining no significant 
results compared to placebo. Two other short-term trials 
(7,29) measured the cognitive effects of glycine based on 
clinical ratings (PANSS cognitive subscale) rather than on 
neuropsychological examination, pointing to a positive result 
in cognitive functioning.
Glycine added to clozapine
Seven trials (2,26-30,45) evaluated the addition of glycine 
to clozapine. Five of them (26,28-30,45) did not find a large 
change of positive symptoms with the adjuvant use of glycine 
in combination with clozapine. One study (2) found worsen-
ing of positive symptoms. Although one trial (27) reported a 
reduction of positive symptoms, the authors did not specify 
whether the results were related to the typical treatment or to 
the clozapine group. 
Although four trials (26,27,29,45) included patients on 
clozapine with a further decrease of negative symptoms, most 
of them (26,27,45) did not distinguish between patients tak-
ing clozapine and patients taking other antipsychotics. Three 
other investigations (2,28,30) showed no beneficial effects on 
negative symptoms.
Cognitive functioning was assessed in only four trials (26-
29). In one investigation (28), specific cognitive tests were 
applied and no effect on cognition was observed. The other 
three studies used the PANSS cognitive subscale, indicating 
beneficial results.
D-cycloserine
Fourteen articles were selected involving the addition of 
D-cycloserine to antipsychotic treatment as usual (Table 2), 
including 9 placebo-controlled double-blind trials (6,12,31-
37) and 5 non-randomized trials (46-50). These studies had 
a variable length of 4 to 24 weeks. Since D-cycloserine is a 
partial agonist, four studies (47-50) compared the effectiveness 
of 5, 15, 50 and 250 mg/day D-cycloserine in an attempt to 
obtain the optimal dosing. The initial results suggested that the 
dosage of 50 mg/day yielded the best results, with worsening 
of symptoms at higher doses (100-250 mg/day) and lack of 
effect at lower doses (5-30 mg/day). 
D-cycloserine added to conventional antipsychotics
Ten trials evaluated the addition of D-cycloserine to typi-
cal antipsychotics (6,12,31-34,36,37,46,47). Seven of them 
(6,12,31-34,47) did not find any significant change in positive 
symptoms and two (with higher dosages, namely 100 and 250 
mg/day) reported worsening of positive symptoms (36,46). 
Beneficial effects on negative symptoms were obtained in 
four trials (6,33,34,47), while four other studies (12,31,32,37) 
did not find a significant change. Two studies (36,46) with 
doses of 100 and 250 mg/day showed worsening of negative 
symptoms.
In addition, one trial (47) demonstrated improvement of 
cognitive functioning at the dose of 50 mg/day, while three 
other trials (12,34,37) did not find significant changes in 
cognitive symptoms. The CONSIST (31) was the largest trial 
evaluating the addition of D-cycloserine to typical antipsychot-
ics and showed no effect on positive, negative or cognitive 
symptoms.
D-cycloserine added to second-generation 
antipsychotics
Four trials evaluated the effect of D-cycloserine added to 
second-generation antipsychotics (6,31,33,50) and none of 
them detected any significant change in positive symptoms. 
Three studies (6,33,50) demonstrated a decrease of negative 
symptoms at the dose of 50 mg/day. On the other hand, these 
trials were conducted on a small numbers of participants and 
the CONSIST (31) showed no significant effect of the increase 
of D-cycloserine to 50 mg/day on negative symptoms. Only 
two trials (31,50) assessed cognitive functioning and showed 
no significant effects.
D-cycloserine added to clozapine
Only three trials evaluated the addition of D-cycloserine to 
clozapine (33,35,48), showing no significant effects on cogni-
tive or positive symptoms. One trial (33) observed ameliora-
tion of negative symptoms, but did not distinguish the type 
of antipsychotics used and consisted of only 9 participants. 
The other two investigations showed worsening of negative 
symptoms when D-cycloserine was added to clozapine.
D-alanine, D-serine and sarcosine
Eight articles involving the addition of these drugs to the 
antipsychotic treatment were selected (Table 3).
D-alanine
There is only one trial involving the addition of D-alanine 
to habitual antipsychotic treatment (Table 3), with the addi-
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tion of D-alanine (100 mg·kg-1·day-1) to typical antipsychot-
ics and to risperidone (11). This study showed effectiveness 
of D-alanine adjuvant treatment to both typical antipsychot-
ics and risperidone on the positive, negative and cogni-
tive domains of schizophrenia. Cognitive functioning was 
assessed by the cognitive subscale of PANSS, with no 
specific cognitive tests. Furthermore, this trial had a small 
sample size, with larger trials being needed to confirm 
these initial results.
D-serine
There were four trials with the addition of D-serine to 
the usual antipsychotic treatment (10,38-40). One trial (10) 
evaluated the addition of D-serine to typical antipsychot-
ics, with amelioration of positive, negative and cognitive 
symptoms. Three trials (10,39,40) evaluated the addition 
of D-serine to second-generation antipsychotics, and two 
of them (10,39) demonstrated good outcomes regarding 
positive, negative and cognitive symptoms. However, one 
study (40) did not find beneficial results in any of the three 
domains. One trial with addition of D-serine to clozapine 
(38) showed no significant effect on the three core symp-
toms of schizophrenia.
Sarcosine
The first trial (14) evaluated the addition of 2 g sarcosine 
to typical antipsychotics and to risperidone, revealing 
an improvement of the positive, negative and cognitive 
symptoms of schizophrenia. The second trial (40) evalu-
ated the addition of sarcosine to risperidone in patients 
with acute exacerbation of schizophrenia, observing an 
overall reduction of symptoms.
These results encouraged research on sarcosine as 
add-on therapy to clozapine (41), which led to no sig-
nificant change in schizophrenia symptoms. Moreover, 
Lane et al. (42) evaluated the effect of sarcosine mono-
therapy on 12 acutely symptomatic drug-free patients 
with schizophrenia, who were randomly assigned to take 
1 or 2 g sarcosine. Overall, there was no significant ef-
fect of sarcosine dose. However, the 5 responders were 
drug-naive patients.
Minocycline
To the best of our knowledge, the antipsychotic 
efficacy of minocycline was first observed in a patient 
with Huntington’s disease (18). There is one case report 
(24) with addition of minocycline to the antipsychotic 
treatment as usual, using a dose of 150 mg/day in two 
cases of acute catatonic schizophrenia. Only the PANSS 
was used weekly for the evaluation of clinical efficacy, 
showing a marked reduction of positive, negative and 
cognitive symptoms. There were no considerable side 
effects, which were clinically evaluated, without using 
scales. The authors reported a considerable decrease 
of psychiatric symptoms, followed by a worsening of 
symptoms after discontinuation of minocycline. However, 
improvement was observed again after the reintroduction 
of minocycline. Both patients remained on minocycline 
co-treatment and were practically symptom-free after one 
year of follow-up, even though the dose of haloperidol 
was reduced. 
Levkovitz et al. (23) examined the efficacy of minocy-
cline as add-on treatment in a double-blind, randomized 
placebo-controlled study conducted on patients with early 
schizophrenia, who were treated with minocycline (N = 
36) or placebo (N = 18). The patients were followed-up 
for 6 months with clinical evaluations by SANS and CGI. 
The cognitive assessment consisted of a computerized 
battery. This trial demonstrated improvement of negative 
symptoms and executive functioning. It is noteworthy 
that positive symptoms were not rated.
Miyaoka et al. (51) published an open-label study 
of minocycline as adjunctive therapy for schizophrenia. 
The researchers evaluated the addition of minocycline 
(150 mg/day) to second-generation antipsychotics in 
22 patients with schizophrenia for a period of 4 weeks. 
The clinical ratings were performed using the PANSS, 
and the positive and negative symptom subscales were 
reduced to 40.4 and 44.0%, respectively, after 4 weeks 
of minocycline co-treatment. The PANSS general psy-
chopathology subscale was reduced to 52.1%. All the 
improvements on the PANSS subscales were maintained 
when scored at the 4-week follow-up time.
Discussion
Possible limitations of glycinergic agents
NMDA agonists
Initial results with glycine and D-cycloserine in ad-
dition to typical and second-generation antipsychotics 
have demonstrated a decrease in negative and cognitive 
symptoms. However, the CONSIST (31) results sug-
gested that neither glycine nor D-cycloserine was effec-
tive for the treatment of negative symptoms or cognitive 
impairment. Nevertheless, this trial had a low percentage 
of subjects treated with typical antipsychotics.
Additionally, the CONSIST (31) data showed no 
correlation between plasma glycine concentration and 
negative symptom response, despite previous findings 
that plasma glycine levels predicted the reduction of 
negative symptoms. Thus, the correlation of plasma 
glycine levels and negative symptom response requires 
further studies.
Overall, the CONSIST (31) results contested the pre-
vious hypotheses of amelioration of negative symptoms 
and cognitive impairment by glycine and D-cycloserine, 
particularly when added to second-generation antipsy-
chotics.
There is only one trial (11) with the addition of D-
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alanine to treatment with typical antipsychotics and 
risperidone. This research showed effectiveness on 
the positive, negative and cognitive domains of schizo-
phrenia. 
The trials of D-serine added to both typical and 
second-generation antipsychotics (10,39) indicated a 
broad symptomatic response in the treatment of chronic 
schizophrenia, but not for acute exacerbation (40).
Glycine transporter-1 inhibitors
The presence of endogenous mechanisms that 
regulate the impact of amino acids administered exog-
enously (8), in addition to the need for high oral doses 
and relative lack of penetration into the CNS (52), is a 
possible limitation of glycinergic agents. Moreover, gly-
cine transporters regulate glycine levels in the synaptic 
cleft. This may limit the impact of dietary glycine in the 
same way that the serotonin precursor L-tryptophan is 
less efficient in increasing serotoninergic transmission 
in comparison to the selective serotonin reuptake inhibi-
tors. As a result, glycine-T1 antagonists may be more 
effective in increasing synaptic glycine and effectively 
potentiating NMDA-R transmission (52). Several glycine-
T1 inhibitors are in clinical and preclinical testing, and 
inhibitors with greater potency are expected to be even 
more effective (8). In view of the early stage of devel-
opment of these compounds, clinical findings are still 
limited to sarcosine. 
Adjunctive therapy with sarcosine has provided 
evidence of broad amelioration of schizophrenia symp-
toms, but with no significant results in monotherapy 
(42). As a result, sarcosine has a good potential as 
adjunctive therapy in addition to typical antipsychotics 
and risperidone.
Clozapine and NMDA-R
The trials that attempted to enhance the effect of clozap-
ine have not been effective or have worsened the psychotic 
frame, suggesting that glycinergic drugs interfere with the 
mechanism of action of clozapine. These results also indi-
cate that clozapine has a particular efficacy related in part 
to the potentiation of neurotransmission mediated by NMDA 
receptors. In fact, clozapine has been effective against the 
neurotoxicity of NMDA antagonists in animal models (53). 
Additionally, a partial agonist of muscarinic M1 receptors 
and an agonist of dopamine D1 receptors have been shown 
to enhance NMDA-R function (53). Hence, clozapine is a 
potent partial agonist of M1 receptors and a partial agonist 
of D1 receptors, which may increase NMDA-R transmission, 
explaining the unique efficacy of this agent (53).
Minocycline
The trials with minocycline add-on treatment to both 
typical and second-generation antipsychotics have shown 
a broad symptomatic response in schizophrenic patients. 
These results warrant further investigation of minocycline 
add-on treatment for patients with schizophrenia.
Mechanisms of action of minocycline
The exact mechanism of action of minocycline remains 
elusive. In addition to inhibiting microglial activation, de-
creasing nitric oxide synthase and having anti-apoptotic 
properties, minocycline has been recently suggested to 
be a positive modulator of the GluR1 subunit receptors 
of AMPA. Although it has been previously suggested that 
AMPA antagonists may offer neuroprotection, Black (54) 
stated that some positive AMPA modulators increase brain-
derived neurotrophic factor production, which in turn has 
been reported to have neuroprotective effects. Furthermore, 
AMPA receptors are distinguished on the basis of subunit 
composition (Glu R1-4) and isoform conformation. The 
subunit composition of the AMPA receptor shows striking dis-
crepancy across the brain (54) and has different properties 
depending on AMPA subunit or splice variant complement. 
Consequently, the clinical effect of an AMPA modulator may 
vary according to the action of different subunits.
NMDA-R signaling dichotomy
Papadia and Hardingham (55) discussed pro-survival 
and pro-death signaling from the NMDA-R, arguing that 
both excessive and poor NMDA-R activities are deleterious 
and cause apoptosis in neurons. For this reason, NMDA-R 
activity shows a bell-shaped curve of neuronal response.
Thus, the phosphoinositide-3-kinase/Akt kinase cas-
cade is an essential pathway for the pro-survival effects of 
NMDA-R stimulation (55). NMDA-R activity also robustly in-
duces cAMP-response-element-binding protein-dependent 
gene expression, which promotes neuronal survival (55).
On the other hand, NMDA-R activity triggers several 
downstream pathways of cell death by Ca2+ influx. One 
of these mechanisms is p38 mitogen-activated protein ki-
nase (MAPK) activation, which can be inversely stimulated 
depending on NMDA-R subtype, subunit composition and 
localization (56).
Therefore, the magnitude of NMDA-R activation, dif-
ferential synaptic versus extrasynaptic NMDA-R effects 
and specific subtypes of NMDA receptors can provide the 
key mediators of neuroprotection instead of neurodegen-
eration (55).
Minocycline and NMDA-R
It is important to point out that minocycline, in addition to 
having the ability to reverse the neurotoxic effects of NMDA 
antagonists, also prevented NMDA-induced injury (57).
Actually, minocycline does not have a direct action on 
NMDA-R and does not regulate intracellular Ca2+ influx 
(58). However, minocycline seems to exert a differential 
control of NMDA-R signaling by preserving pro-survival 
pathways and reducing upstream mechanisms of apoptosis. 
Accordingly, minocycline inhibits p38 MAPK and maintains 
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the activation of phosphoinositide-3-kinase/Akt, which are 
prominently associated with NMDA-R neurochemistry and 
physiology (59).
These mechanisms may underlie the action of minocycline 
on caspase and cytochrome c, since they are later events in cell 
death. Minocycline is an anti-microglial agent and may reduce 
the hypothetical inflammatory component of schizophrenia. 
Besides, minocycline inhibits the activation of all MAPKs. It is 
important to emphasize that these enzymes are essential for 
microglia activation.
Thus, the aforementioned effects of minocycline may play 
an important role in the broad effect of this drug in schizophrenia 
as well as in a wide range of neurological disorders.
Future trends and psychopharmacological targets
The modulation of NMDA-R transmission is a promis-
ing therapeutic approach to the treatment of schizophrenia. 
However, the majority of trials had small sample sizes (less 
than 20 patients) and short durations. Future studies with 
larger numbers of subjects and longer follow-ups are needed 
to corroborate the initial findings. 
Moreover, evaluations of potent glycine-T1 inhibitors along 
with other potential mechanisms for the modulation of NMDA-R 
neurotransmission are promising approaches to the treatment 
of schizophrenia. In addition, metabotropic glutamate (mGlu) 
receptors may be another pharmacological target for the 
enhancement of NMDA-R transmission. Accordingly, positive 
modulators of mGlu5 receptors enhance NMDA-R transmis-
sion and agonists of mGlu2/3 receptors regulate the release 
of glutamate (60). Another possibility lies in the combination of 
drugs with different mechanisms of NMDA-R potentiation.
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